SomaLogic, Inc., a Boulder, CO-based global developer of proteomic discovery and applications for biomedical discovery and clinical diagnostics, added $81M to Series A raise which now totals $214M.
In this second close, additional financial investors include Janus Henderson Investors, Redmile Group, Logos Capital, Revelation Partners, Ziff Capital Healthcare Ventures, Boston Millennia Partners and Millennium Management. Strategic investors from a number of premier organizations that span the current and future proteomics market include Novartis, Amgen, Intermountain Ventures and NEC Solution Innovators, Ltd.
The round was led by Casdin Capital, with participation from Farallon Capital Management, Foresite Capital, funds and accounts advised by T. Rowe Price Associates, Inc., Blue Water Life Science Advisors, Madryn Asset Management, Fiscus Ventures and Reimagined Ventures (affiliates of Magnetar Capital), Monashee Investment Management, Mossrock Capital, Soleus Capital and others.
The company intends to use the funds to improve, expand and commercialize its proteomic products in both the clinical and life science markets.
Led by Chief Executive Officer Roy Smythe, M.D., SomaLogic provides the SomaScan® Platform technology, which offers biopharmaceutical and academic researchers coverage of the proteome for revealing new biology, identifying new drug targets, and assessing the effects of current and potential new drug treatments. The company recently expanded the number of proteins measured by their platform from 5,000 to more than 7,000.